2020
An integrated program of computer-presented and physical cognitive training exercises for children with attention-deficit/hyperactivity disorder
Wexler BE, Vitulano LA, Moore C, Katsovich L, Smith SD, Rush C, Grantz H, Dong J, Leckman JF. An integrated program of computer-presented and physical cognitive training exercises for children with attention-deficit/hyperactivity disorder. Psychological Medicine 2020, 51: 1524-1535. PMID: 32090720, DOI: 10.1017/s0033291720000288.Peer-Reviewed Original ResearchConceptsAttention deficit hyperactivity disorderExperimental medicine approachTAU groupMedicine approachHyperactivity disorderWeeks of treatmentCombined subtypeDiagnosis of ADHDClinical trial designHyperactive-impulsive subtypeAttention-deficit/hyperactivity disorderCross-over designDeficit hyperactivity disorderClinical improvementClinical symptomsRandomized crossCognitive dysfunctionCT groupPathophysiological heterogeneityCONSORT recommendationsTrial designResponse rateChange scoresSubtypesTargeted pathology
2013
Lessons Learned from Open-label Deep Brain Stimulation for Tourette Syndrome: Eight Cases over 7 Years
Motlagh MG, Smith ME, Landeros-Weisenberger A, Kobets AJ, King RA, Miravite J, de Lotbinière AC, Alterman RL, Mogilner AY, Pourfar MH, Okun MS, Leckman JF. Lessons Learned from Open-label Deep Brain Stimulation for Tourette Syndrome: Eight Cases over 7 Years. Tremor And Other Hyperkinetic Movements 2013, 3: 03. PMID: 24255802, PMCID: PMC3822402, DOI: 10.5334/tohm.126.Peer-Reviewed Original ResearchDeep brain stimulationYale Global Tic Severity ScaleTourette syndromeBrain targetsBrain stimulationMedication-refractory Tourette syndromeHomogenous clinical entityOpen-label experienceRefractory Gilles deSerious adverse eventsSelection of patientsRisk of surgeryMidline thalamic nucleiTic Severity ScalePatient-specific outcomesAdverse eventsClinical improvementPostoperative improvementClinical entityGlobus pallidusDBS patientsThalamic nucleiInclusion criteriaSeverity ScaleClinical experienceLONG‐TERM OUTCOME IN ADULTS WITH OBSESSIVE‐COMPULSIVE DISORDER
Bloch MH, Green C, Kichuk SA, Dombrowski PA, Wasylink S, Billingslea E, Landeros‐Weisenberger A, Kelmendi B, Goodman WK, Leckman JF, Coric V, Pittenger C. LONG‐TERM OUTCOME IN ADULTS WITH OBSESSIVE‐COMPULSIVE DISORDER. Depression And Anxiety 2013, 30: 716-722. PMID: 23532944, PMCID: PMC3932438, DOI: 10.1002/da.22103.Peer-Reviewed Original ResearchConceptsLong-term outcomesObsessive-compulsive disorderEvidence-based treatmentsAdult OCD patientsLong-term clinical outcomesSymptom severitySerotonin reuptake inhibitor medicationsOCD patientsPlacebo-controlled trialSerotonin reuptake inhibitorsReuptake inhibitor medicationsPercent of subjectsInitial responseSymptom dimensionsLater symptom severityOCD symptomsSignificant OCD symptomsOCD symptom dimensionsAdult patientsClinical characteristicsClinical improvementEligible subjectsPartial respondersInhibitor medicationReuptake inhibitors
2011
Risperidone-Related Improvement of Irritability in Children with Autism Is not Associated with Changes in Serum of Epidermal Growth Factor and Interleukin-13
Tobiasova Z, van der Lingen KH, Scahill L, Leckman JF, Zhang Y, Chae W, McCracken JT, McDougle CJ, Vitiello B, Tierney E, Aman MG, Arnold LE, Katsovich L, Hoekstra PJ, Volkmar F, Bothwell AL, Kawikova I. Risperidone-Related Improvement of Irritability in Children with Autism Is not Associated with Changes in Serum of Epidermal Growth Factor and Interleukin-13. Journal Of Child And Adolescent Psychopharmacology 2011, 21: 555-564. PMID: 22070180, PMCID: PMC3279715, DOI: 10.1089/cap.2010.0134.Peer-Reviewed Original ResearchConceptsMedication-free subjectsEpidermal growth factorHealthy controlsInflammatory markersIL-13IL-1 receptor antagonistGrowth factorSerum inflammatory markersChemoattractant protein-1Placebo groupClinical improvementBaseline visitIL-17Serum levelsCytokine concentrationsInflammatory moleculesSerum concentrationsClinical trialsHealthy subjectsIL-1Interleukin-13RisperidoneAltered levelsProtein 1Diagnosis of autism